Evidence map›Paper›PMID 34981059›Full record

ArticlebioRxiv : the preprint server for biology2021

Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants.

Lianghui Zhang, Soumajit Dutta, Shiqin Xiong, Matthew Chan, Kui K Chan, Timothy M Fan, Keith L Bailey, Matthew Lindeblad, Laura M Cooper, Lijun Rong and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Lianghui ZhangDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Soumajit DuttaDepartment of Chemical and Biomolecular Engineering, University of Illinois, Urbana, IL 61801, USA.
Shiqin XiongDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Matthew ChanDepartment of Chemical and Biomolecular Engineering, University of Illinois, Urbana, IL 61801, USA.
Kui K ChanCyrus Biotechnology, Inc., Seattle, WA 98101, USA.
Timothy M FanDepartment of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine, Urbana, IL 61802, USA.
Keith L BaileyDepartment of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine, Urbana, IL 61802, USA.
Matthew LindebladToxicology Research Laboratory, Department of Pharmacology and Regenerative Medicine, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Laura M CooperDepartment of Microbiology and Immunology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Lijun RongDepartment of Microbiology and Immunology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Anthony F GugliuzzaDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Diwakar ShuklaDepartment of Chemical and Biomolecular Engineering, University of Illinois, Urbana, IL 61801, USA.
Erik ProckoDepartment of Biochemistry, University of Illinois, Urbana, IL 61801, USA.
Jalees RehmanDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Asrar B MalikDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
University of Illinois Urbana-Champaign · USIllinois College · USCyrus Biotechnology

Funding

TRPC6 Regulation of Lung Endothelial Barrier FunctionP01HL060678 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MALIK, ASRAR B. · 2000 to 2020
$40.1M
TRAINING PROGRAM IN LUNG BIOLOGY AND PATHOBIOLOGYT32HL007829 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DOLLY MEHTA · 1995 to 2026
$15.6M
Endothelial Regeneration Following Lung Vascular InjuryR01HL118068 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MALIK, ASRAR B., REHMAN, JALEES · 2014 to 2017
$2.4M
Nanoparticle Targeting of Neutrophil Subpopulations in Inflammatory Lung InjuryR01HL149300 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MALIK, ASRAR B., REHMAN, JALEES · 2019 to 2022
$2.4M
Amplification Mechanisms of Lung Endothelial Inflammation During Acute Lung InjuryR01HL152515 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REHMAN, JALEES · 2021 to 2024
$2.3M
Endothelial antigen presentation to T cells as a pathogenic mechanism in influenza-induced acute lung injury.R01HL157489 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, LIANGHUI · 2021 to 2025
$2.0M
Optimization of a broad and potent decoy receptor for SARS-associated virusesR43AI162329 · NIAID · ORTHOGONAL BIOLOGICS, INC. · PI CHAN, KUI KIU · 2021 to 2021
$257k
Endothelial Instruction of Macrophage Fate in Inflammatory InjuryR01HL154538 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REHMAN, JALEES · 2021 to 2021
$128k
NHLBI NIH HHS P01 HL060678NHLBI NIH HHS R01 HL118068NHLBI NIH HHS R01 HL149300NHLBI NIH HHS R01 HL152515NHLBI NIH HHS R01 HL154538NHLBI NIH HHS R01 HL157489NHLBI NIH HHS T32 HL007829NIAID NIH HHS R43 AI162329
6 · The paper itself

Abstract

Vaccine hesitancy and continuing emergence of SARS-CoV-2 variants of concern that may escape vaccine-induced immune responses highlight the urgent need for effective COVID-19 therapeutics. Monoclonal antibodies used in the clinic have varying efficacies against distinct SARS-CoV-2 variants; thus, there is considerable interest in engineered ACE2 peptides with augmented binding affinities for SARS-CoV-2 Spike protein. These could have therapeutic benefit against multiple viral variants. Using molecular dynamics simulations, we show how three amino acid substitutions in an engineered soluble ACE2 peptide (sACE2

Identifiers

PMID34981059
PMCPMC8722596
OpenAlexW4200194190

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.